Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as “untargetable”; today, we see the birth of new molecules that ta...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/2/395 |
| _version_ | 1827756790491643904 |
|---|---|
| author | Sara Cherri Laura Melocchi Laura Gandolfi Giulio Rossi Alberto Zaniboni |
| author_facet | Sara Cherri Laura Melocchi Laura Gandolfi Giulio Rossi Alberto Zaniboni |
| author_sort | Sara Cherri |
| collection | DOAJ |
| description | In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as “untargetable”; today, we see the birth of new molecules that target one of the variants of the KRAS mutation, KRAS G12C, having a significant impact on the therapeutic options for other malignancies, such as metastatic lung cancer. This fundamental step forward has stimulated scientific research on other potential targets of KRAS, both indirect and direct, and combination treatments aiming to overcome the mechanisms of resistance to these drugs that decrease in efficacy in colorectal cancer. What was once a negative predictive marker of response to anti-EGFR drugs today has become a potential target for targeted treatments. In turn, the prognostic role of the mutation has become extremely interesting, making it a potentially useful element in therapeutic decision-making, not only regarding oncological treatments but also in a more complex and complete manner within a global vision of the patient, involving other figures on the multidisciplinary team, such as surgeons, radiotherapists, and interventional radiologists. |
| first_indexed | 2024-03-11T08:32:12Z |
| format | Article |
| id | doaj.art-1e7122fa631e4200a8e1159475a63092 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-11T08:32:12Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-1e7122fa631e4200a8e1159475a630922023-11-16T21:40:41ZengMDPI AGLife2075-17292023-01-0113239510.3390/life13020395Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated TumorsSara Cherri0Laura Melocchi1Laura Gandolfi2Giulio Rossi3Alberto Zaniboni4Department of Clinical Oncology, Fondazione Poliambulanza, 25124 Brescia, ItalyDepartment of Anatomical Pathology, Fondazione Poliambulanza, 25124 Brescia, ItalyDepartment of Anatomical Pathology, Fondazione Poliambulanza, 25124 Brescia, ItalyDepartment of Anatomical Pathology, Fondazione Poliambulanza, 25124 Brescia, ItalyDepartment of Clinical Oncology, Fondazione Poliambulanza, 25124 Brescia, ItalyIn recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as “untargetable”; today, we see the birth of new molecules that target one of the variants of the KRAS mutation, KRAS G12C, having a significant impact on the therapeutic options for other malignancies, such as metastatic lung cancer. This fundamental step forward has stimulated scientific research on other potential targets of KRAS, both indirect and direct, and combination treatments aiming to overcome the mechanisms of resistance to these drugs that decrease in efficacy in colorectal cancer. What was once a negative predictive marker of response to anti-EGFR drugs today has become a potential target for targeted treatments. In turn, the prognostic role of the mutation has become extremely interesting, making it a potentially useful element in therapeutic decision-making, not only regarding oncological treatments but also in a more complex and complete manner within a global vision of the patient, involving other figures on the multidisciplinary team, such as surgeons, radiotherapists, and interventional radiologists.https://www.mdpi.com/2075-1729/13/2/395cancerchemotherapycolon cancerKRAStarget therapymultidisciplinary team |
| spellingShingle | Sara Cherri Laura Melocchi Laura Gandolfi Giulio Rossi Alberto Zaniboni Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors Life cancer chemotherapy colon cancer KRAS target therapy multidisciplinary team |
| title | Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors |
| title_full | Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors |
| title_fullStr | Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors |
| title_full_unstemmed | Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors |
| title_short | Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors |
| title_sort | integrated decision making in the treatment of colon rectal cancer the case of kras mutated tumors |
| topic | cancer chemotherapy colon cancer KRAS target therapy multidisciplinary team |
| url | https://www.mdpi.com/2075-1729/13/2/395 |
| work_keys_str_mv | AT saracherri integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors AT lauramelocchi integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors AT lauragandolfi integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors AT giuliorossi integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors AT albertozaniboni integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors |